Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Fineline Cube Jan 16, 2026
Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Fineline Cube Jan 16, 2026
Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Company Deals Digital

ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine

Fineline Cube Mar 6, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...

Company

Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies

Fineline Cube Mar 6, 2024

Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting...

Company Drug

Formosa Pharmaceuticals Secures FDA Nod for New Steroidal Eye Drug, Set to Launch via Eyenovia

Fineline Cube Mar 6, 2024

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has received approval from the US Food and Drug Administration...

Company Deals

MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe

Fineline Cube Mar 6, 2024

MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins...

Company Drug

Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates

Fineline Cube Mar 6, 2024

Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...

Company Drug

Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study

Fineline Cube Mar 6, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...

Company Drug

Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars

Fineline Cube Mar 6, 2024

The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter

Fineline Cube Mar 6, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...

Company Drug

Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment

Fineline Cube Mar 6, 2024

Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC

Fineline Cube Mar 6, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...

Policy / Regulatory

China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms

Fineline Cube Mar 5, 2024

Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of...

Company Drug

EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications

Fineline Cube Mar 5, 2024

The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...

Company Drug

Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis

Fineline Cube Mar 5, 2024

The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...

Policy / Regulatory

China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024

Fineline Cube Mar 5, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...

Company Drug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

Fineline Cube Mar 5, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...

Company Deals

Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases

Fineline Cube Mar 5, 2024

California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...

Company Drug

Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer

Fineline Cube Mar 5, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...

Company

Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management

Fineline Cube Mar 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...

Company Deals

Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics

Fineline Cube Mar 5, 2024

Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...

Posts pagination

1 … 338 339 340 … 610

Recent updates

  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
  • Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
  • Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
  • J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions
  • Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.